Tal Zvi Zaks
Known title: DirectorCIK: 0001690927
Associated companies
this person other insiders at TEVA
Transaction History
| TEVA | ▼ Sell | Open Market | 17 | $593 | 8/5/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 14,492 | — | 6/5/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 9,632 | — | 6/6/2025 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 21,108 | — | 6/15/2024 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 15,810 | — | 8/4/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 12,205 | — | 11/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Teva Receives FDA Approval for Weltruza, Announces R&D Day
Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.
Teva Receives FDA Approval for Weltruza, Announces R&D Day. Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.